(IPCI) Awaiting 5 FDA approvals (Mcap 55 M )= MULTIBAGGER
This Unknown low float Stock awaiting 5 FDA approvals and will rise to 7 by year end .IPCI has 15 Drugs in Pipeline many nearing ANDA/NDA filing including a potential Blockbuster .
Market Cap 55 Mil / Cash 8.5 M / Burn-rate 4.5 M per Year = Enough Cash until Profitability which will be reached by next Year .
2 FDA approvals and many New Partnership coming soon.
MY Target is $15++ for 2011..A FANTASTIC INVESTMENT FOR BIO-FANS .
Market Cap: 55 M Cash: 8.5 M Price: 3.55 $
Shares Out: 15.9 Mil..(13 Mil Shares held by Insiders/Institutions)
"The filing of a generic version of Seroquel XR® is one of the Company's performance milestones for 2011 and another important addition to our product portfolio filed for approval with the FDA, which includes generics of Focalin XR®, Effexor XR®, Protonix® DR and Glucophage® XR," commented Dr. Isa Odidi, CEO of Intellipharmaceutics. "These filings not only provide further validation of our Hypermatrix™ technology, they clearly demonstrate the flexibility of our technology to efficiently and effectively match a number of drug delivery profiles."
Intellipharmaceutics now has five ANDAs awaiting FDA approval with reported sales for branded and generic versions of these products being approximately $8 billion in 2010. The Company develops both ANDA product candidates and new drugs through the New Drug Application (NDA) 505(b)(2) regulatory pathway.